Merkel cell carcinoma
Oncology · 2018–2026
3decisions
2medicines
3carried consumer input
11individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| retifanlimab Treatment of metastatic or recurrent, locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation. | Mar 2026 | Recommended with restriction | 4 individuals Rare Cancers Australia · NeuroEndocrine Cancer Australia |
| retifanlimab Treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation. | Nov 2025 | Deferred | 4 individuals Rare Cancers Australia · NeuroEndocrine Cancer Australia |
| avelumab Second-line and first-line treatment of metastatic Merkel cell carcinoma (mMCC) in patients whose disease has progressed following chemotherapy, or who have… | Jul 2018 | Recommended | 3 individuals |
Who spoke
Rare Cancers Australia · NeuroEndocrine Cancer Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.